Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCL

April 14, 2021
Brian Till, MD

Partner | Cancer Centers | <b>SCCA</b>

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.

Brian Till, MD, a physician at the Seattle Cancer Care Alliance, as well as an associate professor in the Division of Medical Oncology at the University of Washington School of Medicine and an associate professor of Clinical Research Division at the Fred Hutchinson Cancer Research Center, discusses the safety and efficacy of lisocabtagene maraleucel (liso-cel; Breyanzi) compared with other products under exploration in patients with mantle cell lymphoma (MCL).

Although the CAR T-cell product has only been examined in a small cohort of patients with MCL, with a short median follow-up in the phase 1 TRANSCEND-NHL-001 (NCT02631044), preliminary data have been promising, according to Till. Among the 32 patients treated with liso-cel, the overall response rate was 84%, and two-thirds of patients experienced a complete response, Till says.

These results were similar to those reported with brexucabtagene autoleucel (Tecartus) in patients with MCL, although the safety profiles of the 2 products differed; a lower incidence of severe cytokine release syndrome was reported with liso-cel, Till notes. The toxicities observed with liso-cel in patients with MCL were also comparable to those observed with the agent in large B-cell lymphoma, Till adds. The 2 therapies also differ in terms of outpatient vs inpatient administration, Till concludes.